Next Article in Journal
Proton Beam Therapy without Fiducial Markers Using Four-Dimensional CT Planning for Large Hepatocellular Carcinomas
Next Article in Special Issue
Update on Immunohistochemistry for the Diagnosis of Lung Cancer
Previous Article in Journal
Nano-Pulse Stimulation Ablates Orthotopic Rat Hepatocellular Carcinoma and Induces Innate and Adaptive Memory Immune Mechanisms that Prevent Recurrence
Article Menu
Issue 3 (March) cover image

Export Article

Open AccessFeature PaperReview
Cancers 2018, 10(3), 70; https://doi.org/10.3390/cancers10030070

Any Place for Immunohistochemistry within the Predictive Biomarkers of Treatment in Lung Cancer Patients?

1
Laboratory of Clinical and Experimental Pathology, Côte d’Azur University, FHU OncoAge, Pasteur Hospital, 30 Avenue de la voie Romaine, 06001 Nice CEDEX 01, France
2
Hospital-Integrated Biobank (BB-0033-00025), Pasteur Hospital, 30 Avenue de la voie Romaine, 06001 Nice CEDEX 01, France
*
Author to whom correspondence should be addressed.
Received: 27 January 2018 / Revised: 25 February 2018 / Accepted: 9 March 2018 / Published: 13 March 2018
(This article belongs to the Special Issue Immunohistochemistry and Cancer Diagnosis)
View Full-Text   |   Download PDF [6702 KB, uploaded 13 March 2018]   |  

Abstract

The identification of certain genomic alterations (EGFR, ALK, ROS1, BRAF) or immunological markers (PD-L1) in tissues or cells has led to targeted treatment for patients presenting with late stage or metastatic lung cancer. These biomarkers can be detected by immunohistochemistry (IHC) and/or by molecular biology (MB) techniques. These approaches are often complementary but depending on, the quantity and quality of the biological material, the urgency to get the results, the access to technological platforms, the financial resources and the expertise of the team, the choice of the approach can be questioned. The possibility of detecting simultaneously several molecular targets, and of analyzing the degree of tumor mutation burden and of the micro-satellite instability, as well as the recent requirement to quantify the expression of PD-L1 in tumor cells, has led to case by case development of algorithms and international recommendations, which depend on the quality and quantity of biological samples. This review will highlight the different predictive biomarkers detected by IHC for treatment of lung cancer as well as the present advantages and limitations of this approach. A number of perspectives will be considered. View Full-Text
Keywords: predictive biomarkers; lung cancer; immunohistochemistry; immunocytochemistry; immune-oncology predictive biomarkers; lung cancer; immunohistochemistry; immunocytochemistry; immune-oncology
Figures

Figure 1a

This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. (CC BY 4.0).
SciFeed

Share & Cite This Article

MDPI and ACS Style

Hofman, V.; Lassalle, S.; Bence, C.; Long-Mira, E.; Nahon-Estève, S.; Heeke, S.; Lespinet-Fabre, V.; Butori, C.; Ilié, M.; Hofman, P. Any Place for Immunohistochemistry within the Predictive Biomarkers of Treatment in Lung Cancer Patients? Cancers 2018, 10, 70.

Show more citation formats Show less citations formats

Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Related Articles

Article Metrics

Article Access Statistics

1

Comments

[Return to top]
Cancers EISSN 2072-6694 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top